Evidence map›Paper›PMID 27174914›Full record

ArticleOncotarget2016

p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.

Dandan Wu, Jie Cheng, Geng Sun, Shengjie Wu, Min Li, Zhongyuan Gao, Sulan Zhai, Ping Li, Dongming Su, Xuerong Wang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. MiR-449a antagonizes EMT through IL-6-mediatedMolecular therapy. Nucleic acids · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Dandan WuDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Jie ChengDepartment of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Geng SunDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Shengjie WuDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Min LiDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Zhongyuan GaoDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Sulan ZhaiDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Ping LiDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Dongming SuCenter for Clinical Pathology and Laboratory, Affiliated Hospital of Yifu, Nanjing Medical University, Nanjing, Jiangsu Province 211166, China.
Xuerong WangDepartment of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China.
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide and a common cause of cancer-related death, with a 5-year survival rate of less than 60%. IL-6 has been suggested to play an important role in cancer metastasis, but its mechanism in HNSCC has not been fully clarified. p70S6K has been reported to induce epithelial-mesenchymal transition (EMT) of ovarian cancer, but its role in HNSCC remains unknown. In this study, we found that p70S6K and IL-6 were upregulated in high-metastatic HNSCC cell lines that underwent EMT when compared to paired low-metastatic cell lines. Overexpression of p70S6K promoted EMT and migration of HNSCC cells, while downregulation of p70S6K attenuated IL-6-induced EMT and cell migration. Furthermore, IL-6-induced p70S6K activation was attenuated by inhibitors of the PI3K/Akt/mTOR, MAPK/ERK, and JAK/STAT3 signaling pathways, suggesting that it located downstream of these pathways. These findings suggest that p70S6K promotes IL-6-induced EMT and metastasis of HNSCC. Targeting p70S6K for HNSCC therapy may benefit patients through the inhibition of tumor growth, as well as metastasis.

Indexed as

Gene Expression Regulation, NeoplasticCarcinoma, Squamous CellCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionHead and Neck NeoplasmsHumansInterleukin-6Mitogen-Activated Protein KinasesNeoplasm MetastasisPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRibosomal Protein S6 Kinases, 70-kDaRNA InterferenceSignal TransductionTOR Serine-Threonine KinasesInterleukin-6Mitogen-Activated Protein KinasesMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRibosomal Protein S6 Kinases, 70-kDaTOR Serine-Threonine Kinasesepithelial-mesenchymal transitionHNSCCIL-6metastasisp70S6K

Identifiers

PMID27174914
PMCPMC5095019
OpenAlexW2351856897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.